Skip to content

Intraoperative Posterior Cruciate Ligament (Transcruciate) Injection After Total Knee Arthroplasty (TKA)

Reducing Posterior Knee Pain Following Total Knee Arthroplasty Using an Intraoperative Posterior Cruciate Ligament (Transcruciate) Injection

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01345604
Enrollment
50
Registered
2011-05-02
Start date
2011-05-31
Completion date
2013-05-31
Last updated
2016-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthroplasty, Replacement, Knee

Brief summary

his study is being done because total knee replacements can leave patients with considerable pain after surgery. Therefore, many studies have been done to find the best ways to control knee pain after the surgery. Currently, a popular approach is to use many different techniques to control the pain. This includes injecting freezing (local anesthetic) into the spinal column (spinal anesthetic), injecting freezing close to the nerves of the knee and using various kinds of medications (e.g. narcotics and anti-inflammatory medications). Studies have shown using this a combination of techniques can reduce pain and allow earlier discharge from the hospital. However, one downside to this approach is it does not usually control the pain in the back of the knee. One new technique has been used to try and overcome this. This technique is called a posterior cruciate ligament block or PCL block. It involves injecting a drug into the back of the knee which will block the nerves in this area. Sometimes the investigators refer to this as freezing. The purpose of our study is to determine whether this PCL Block will improve pain after the total knee replacement surgery. The investigators will also determine whether this technique will improve movement in the knee and lessen narcotic usage after the surgery.

Interventions

PROCEDUREtranscruciate injection of 20cc of normal saline

Group 2 (control group) will receive a transcruciate injection of 20cc of normal saline through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).

PROCEDUREtranscruciate injection of 20 cc of 0.5% Ropivacaine

Group 1 (study group) will receive a transcruciate injection of 20 cc of 0.5% Ropivacaine through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).

Sponsors

Saskatoon Health Region
CollaboratorOTHER
University of Saskatchewan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
16 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* American Society of Anesthesiologists' (ASA) physical status classification (ASA) I and II patients undergoing unilateral total knee arthroplasty at Saskatoon City Hospital * Patients recruited from the practice of 4 orthopedic surgeons

Exclusion criteria

* Inability to obtain informed consent * Simultaneous bilateral total knee arthroplasty or revision cases * Preexisting neurological deficits in the distribution of the femoral nerve or known diagnosis of peripheral neuropathy * Coagulopathies * Infection either systemically or at the needle insertion sites * Allergies to local anesthetics or opioids * Patients with a history of narcotic dependency or chronic pain * ASA III and IV * Body Mass Index (BMI) \> 40

Design outcomes

Primary

MeasureTime frame
Knee flexionup to one week postoperative

Secondary

MeasureTime frameDescription
Postoperative pain scorein PACU , on ward (baseline), and post-op day 1 & 2 at 10am & 6pmPain scores will be recorded at rest and on attempt of achieving a 90 degree passive flexion of the knee.
Total narcotic consumptionup to 1 week postoperative

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026